MedPath

A prospective co-hort study about efficacy and safety for sorafenib treatment in patients with advanced hepatocellular carcinoma.

Not Applicable
Recruiting
Conditions
Hepatocellular carcinoma
Registration Number
JPRN-UMIN000007427
Lead Sponsor
Division of Gastroenterology, Department of Medicine Kurume University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

An infectious disease of the activity (but except the viral hepatitis) An overlap cancer of the activity A past of sensitivity to iodocontrast media A pregnant woman, a nursing girl may be pregnant The case that the medical attendant judged to be inappropriate as an object of the final examination for reasons of others (problem cases such as a patient does not hear instructions or the support of the family not being provided)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome of this study is the overall survival time.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath